COR · 8-K · 20260805PR000032

Guidance and Outlook

Cencora, Inc. · 2026-08-05 · Importance 73 · Surprise 76 · No source text

Cencora raised fiscal 2026 adjusted diluted EPS guidance from $17.70-$17.90 to $17.75-$17.95. The company expects consolidated revenue growth of 4%-6%, adjusted operating income growth of 13%-14%, and adjusted free cash flow of approximately $3.0 billion for fiscal 2026. Guidance includes approximately $490 million of net interest expense and capital expenditures of approximately $900 million, compared with fiscal 2025 capital expenditures of $668 million. International Healthcare Solutions revenue guidance is approximately 8% growth on an as-reported basis, with further constant-currency details referenced in the company’s investor presentation.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
revenuepositiveprobable+9.5%Cencora expects fiscal 2026 revenue growth of 4% to 6% (2026 Guidance) versus fiscal 2025 actuals $321.3B
net_incomepositiveprobableCompany raised fiscal 2026 adjusted diluted EPS guidance to a range of $17.75 to $17.95 (from prior $17.70 to $17.90)
operating_incomeunclearprobableThe Company has provided non-GAAP fiscal year 2026 guidance for diluted earnings per share, operating income, effective income tax rate,…
cashunclearprobableThe Company has provided non-GAAP fiscal year 2026 guidance for diluted earnings per share, operating income, effective income tax rate,…